Brepocitinib cleared dermatomyositis skin disease faster and more often than placebo

Design

Prespecified secondary analysis of a 52-week, phase 3, double-blind, placebo-controlled randomised trial

Population

241 adults with dermatomyositis and active skin and muscle disease at 90 sites in 20 countries

Primary outcome

Change in CDASI-A and clinically meaningful CDASI-A response (key secondary)

Effect

CDASI-A difference −3.0 (95% CI −4.6 to −1.4); response 33.3% vs 17.7%

VALOR was a 52-week, double-blind, placebo-controlled phase 3 trial of brepocitinib, an oral TYK2 and JAK1 inhibitor, in 241 adults with active skin and muscle dermatomyositis at 90 sites. This prespecified secondary analysis looked at skin outcomes.

From week 4, brepocitinib 30 mg reduced cutaneous disease activity more than placebo (CDASI-A change −6.4 vs −3.5; difference −3.0, 95% CI −4.6 to −1.4). A clinically meaningful skin response occurred in 33.3% vs 17.7%, itch remission in 38.3% vs 19.0%, and skin-related quality of life improved by about 12 points more. Among those with moderate to severe skin disease, 45.7% vs 21.8% reached clear or almost clear skin at week 52. Safety was in line with other JAK and TYK2 inhibitors.

Cutaneous dermatomyositis is often the most refractory and distressing part of the disease. This is promising, but these were secondary and exploratory endpoints of a trial whose primary outcome was overall disease response, and the drug's licensing status for dermatomyositis was not reported.

• Score skin activity separately from muscle disease when reviewing dermatomyositis — a validated index such as CDASI makes response visible.
• Ask about itch at every visit; it improved substantially with brepocitinib and is often under-recorded.
• Screen every new adult dermatomyositis patient for underlying malignancy, whatever skin treatment is planned.
• Expect the usual JAK inhibitor safety checks — infection, blood counts, lipids — if brepocitinib becomes available.

Why it matters

Skin disease often persists in dermatomyositis after muscle disease is controlled, and few treatments target it with trial evidence.

Don't overread it

These skin results are secondary and exploratory endpoints; the remission figures come from a subgroup with moderate to severe skin disease.

The statistics, in plain English

A difference of 15.1 percentage points in meaningful skin response means about one extra responder for every seven treated. The interval (1.7 to 28.6) is wide, so the true benefit could be smaller. Results in a subgroup — here, those with worse skin disease — are less reliable than results in the whole trial.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.